- Home
- ALEC vs BGH Comparison
ALEC vs BGH Comparison
Compare ALEC & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALEC | BGH |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.8M | 259.9M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ALEC | BGH |
|---|---|---|
| Price | $2.49 | $12.53 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.90 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 118.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $900.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $12.37 |
| 52 Week High | $2.84 | $15.35 |
Technical Indicators
Market Signals| Indicator | ALEC | BGH |
|---|---|---|
| Relative Strength Index (RSI) | 61.48 | 40.57 |
| Support Level | $1.90 | $12.37 |
| Resistance Level | $2.65 | $14.35 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 64.22 | 27.35 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.